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PURPOSE. To investigate longitudinal changes of subbasal nerve plexus (SNP) morphology and
its relationship with conventional measures of neuropathy in individuals with diabetes.
METHODS. A cohort of 147 individuals with type 1 diabetes and 60 age-balanced controls
underwent detailed assessment of clinical and metabolic factors, neurologic deficits,
quantitative sensory testing, nerve conduction studies, and corneal confocal microscopy at
baseline and four subsequent annual visits. The SNP parameters included corneal nerve fiber
density (CNFD), branch density (CNBD), and fiber length (CNFL), and were quantified using a
fully automated algorithm. Linear mixed models were fitted to examine the changes in corneal
nerve parameters over time.
RESULTS. At baseline, 27% of the participants had mild diabetic neuropathy. All SNP parameters
were significantly lower in the neuropathy group compared with controls (P < 0.05). Overall,
89% of participants examined at baseline also completed the final visit. There was no clinically
significant change to health and metabolic parameters and neuropathy measures from
baseline to the final visit. Linear mixed model revealed a significant linear decline of CNFD
(annual change rate, 0.9 nerve/mm2, P ¼ 0.01) in the neuropathy group compared with
controls, which was associated with age (b ¼ 0.06, P ¼ 0.04) and duration of diabetes (b ¼
0.08, P ¼ 0.03). In the neuropathy group, absolute changes of CNBD and CNFL showed
moderate correlations with peroneal conduction velocity and cold sensation threshold,
respectively (r, 0.38 and 0.40, P < 0.05).
CONCLUSIONS. This study demonstrates dynamic small fiber damage at the SNP, thus providing
justification for our ongoing efforts to establish corneal nerve morphology as an appropriate
adjunct to conventional measures of diabetic peripheral neuropathy.
Keywords: corneal confocal microscopy, diabetes, natural history
Diabetic neuropathy is a substantial and burdensomecomplication of diabetes, affecting up to 50% of these
individuals.1 Diabetic peripheral neuropathy (DPN), which is
the most common form of neuropathy, manifests as a distal,
symmetric polyneuropathy that begins in the lower extremities
and may progress proximally.2 Diabetic peripheral neuropathy
leads to morbidity in diabetic patients in the form of painful
neuropathy and foot ulceration with consequent lower limb
amputation.3 It accounts for reduced quality of life and imposes
a significant economic burden that affects both individuals and
society.4,5
Several established tests are commonly used for screening,
detection, and assessment of DPN and to monitor its
progression. Most of these tests examine neuronal function;
however, direct observation of nerve structure also is possible.
Neurologic symptoms and signs, quantitative sensory tests
(QST), and nerve conduction studies (NCS) are the most
commonly used tests for DPN.6 Indeed, symptoms, neurolog-
ical deficits, and NCS constitute the basis on which diabetic
neuropathy is diagnosed. Quantitative sensory tests provide
quantitative measures of sensation; however, these tests require
cooperation and concentration of the examinee and they also
may be affected by anthropometric variables.7 Although recent
studies have shown that the proficiency of QST assessment is
adequate,8 the reproducibility of symptoms and signs9 and
NCS10 has been shown to be limited. Furthermore, studies in
patients with impaired glucose tolerance (IGT)11 and recently
diagnosed type 2 diabetes12 show a marked small fiber
neuropathy accompanying large fiber dysfunction.
Quantification of nerve pathology is possible through direct
morphometric examination of nerves, including sural nerve
biopsy13 and skin biopsy.14 However, these techniques are
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invasive, require expertise for quantification, and cannot be
repeated from the same site for longitudinal studies. Accurate
detection and estimation of progression are needed, especially
to test putative treatments, which may alleviate the condition,
and/or prevent or delay the development of sequelae. As
reviewed in more detail elsewhere,15,16 based on the
pathogenesis of DPN, several potential therapeutic approaches
have been developed targeting these mechanisms; however,
apart from glucose control and pain management, currently
there is no approved treatment for DPN.15,17
Lack of a sensitive, accurate, and reliable clinical end point
has been one of the obstacles in mounting treatment trials for
DPN.18 Growing evidence supports a prominent association
between corneal subbasal nerve plexus (SNP) morphology
measured with corneal confocal microscopy (CCM) and DPN.
Corneal confocal microscopy as a quick, noninvasive, and
reiterative technique has a demonstrated capacity to detect
early small nerve fiber damage in diabetic patients,19 and
diagnose20–22 and classify severity of DPN.23,24 Conventional
measures of neuropathy and corneal nerve parameters also are
related.21,23,25 Furthermore, the demonstration of early corneal
nerve regeneration following simultaneous pancreas and
kidney transplantation26 and optimized glycemic and lipid
control in an observational study27 suggest that CCM may well
fulfill some of the criteria for a surrogate end point for diabetic
neuropathy.
To our knowledge, no study has been conducted to date
concerning the natural course of the SNP structure over time
in diabetic patients. Therefore, in this study, we sought to
investigate the natural history of the SNP morphology in type 1
diabetic individuals without and with mild neuropathy.
Furthermore, the longitudinal relationship between changes
in corneal nerve structure and established measures of
neuropathy in individuals with diabetes also was addressed.
METHODS
Study Design and Participants
This prospective, observational, longitudinal study was con-
ducted following approval from Queensland University of
Technology, Princess Alexandra Hospital, and Mater Hospital
research ethics committees as a part of the LANDMark study28
in Brisbane, Australia. Before their enrollment, written
informed consent was obtained from all participants and the
research adhered to the tenets of the Declaration of Helsinki.
Based on the inclusion/exclusion criteria, 147 type 1 diabetic
participants were recruited from the Diabetes and Endocrinol-
ogy Research Centre at Princess Alexandra and Mater hospitals
and the general population in Brisbane. Sixty healthy
participants, without peripheral neuropathy and/or diabetes
also were recruited as controls. All participants were assessed
at baseline and assessments continued for four annual
subsequent visits (five time points in total and approximately
960 case visits). Participants were excluded in this study for
any of the following: history of ocular trauma or surgery, ocular
disease or systemic disease with potential corneal effect, and
systemic disease (other than diabetes). Other causes of
neuropathy were excluded. Diabetic participants with moder-
ate and severe neuropathy also were excluded. All participants
underwent neurologic and medical evaluation as well as ocular
screening (visual acuity, slit lamp examination, and IOP) and
CCM, which were repeated annually.
For the definition of DPN, we followed accepted criteria29
that rely on the presence of abnormal electrophysiological
finding, based on age-matched controls at the site, in addition
to clinical signs and/or symptoms, which were defined as one
or more of the following: neuropathy disability score (NDS) of
3 or more of 10,30 or diabetic neuropathy symptom score
(DNSS) of 1 or more of 4.31 The methods used during this study
to assess neuropathy and clinical and metabolic factors have
been reported in detail elsewhere28 and will be described only
briefly here.
Assessment of Neuropathy
Neuropathy Signs and Symptoms. The NDS, which is a
scale of 0 to 10, was used to assess neurological deficits. This
measure included assessment of vibration, pin-prick, and
temperature perception as well as presence or absence of
ankle reflexes in both lower limbs. Diabetic neuropathy
symptom score, a scale of 0 to 4, was used to assess symptoms
of neuropathy.
Quantitative Sensory Tests. Quantitative sensory tests
comprised of vibration perception, measured on the plantar
surface of the big toe, and thermal (warm and cold) sensation
which was assessed on the dorsal surface of the foot on the
hand-dominant side.
Nerve Conduction Studies. Peroneal motor nerve con-
duction velocity (ankle to fibula head), amplitude (ankle to
extensor digitorum brevis), and F-wave latency were deter-
mined on the hand-dominant side of the participants.
General Health and Metabolic Assessment
At each visit, all participants underwent assessment of height,
weight, body mass index (BMI), blood pressure, HbA1c, and
lipid profile.
Corneal Confocal Microscopy and Image Analysis
Corneal confocal microscopy was carried out using the
Rostock Cornea Module in combination with an HRT 3
confocal microscope (Heidelberg Engineering, Heidelberg,
Germany). Eight images of the SNP, showing in focus nerves
and not overlapping more than 20%,32 were acquired from the
center of cornea on the hand-dominant side using manual
focusing and section mode. Automatic segmentation and
quantification of the SNP parameters, including corneal nerve
fiber density (CNFD), branch density (CNBD), and fiber length
(CNFL), were performed using ACCMetrics (University of
Manchester, Manchester, UK),33 which is a fully automated
analytical system. The SNP parameters for each participant
were the average value obtained from the eight captured
images and expressed in the unit of number per millimeter
squared for CNFD and CNBD, and millimeter per millimeter
squared for CNFL.
Intra- and Interobserver Repeatability of the SNP
Parameters
To ascertain the repeatability of the SNP parameters from one
time to another, test-retest was carried out by performing CCM
examination and automated image analysis for 16 participants,
including 10 with diabetes and 6 healthy controls by a single
operator as described above. Each participant was examined
twice, on the same day of examination, at least 30 minutes
apart. No significant differences were found between test and
retest measurements for CNFD, CNBD, and CNFL (P¼0.59, P¼
0.88, and P ¼ 0.94, respectively). The intraclass correlation
coefficients (ICC) and coefficient of repeatability (CoR) were
0.81 and 0.08 for CNFD, 0.84 and 0.20 for CNBD, and 0.90 and
0.03 for CNFL, respectively.
To assess the interobserver reproducibility of the SNP
parameters, 11 participants (6 with diabetes and 5 healthy
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controls) underwent CCM examinations twice by two experi-
enced operators on the same day of examination. The
differences of the SNP parameters were not statistically
significant for two observers (CNFD, P ¼ 0.29; CNBD, P ¼
0.22 and CNFL, P ¼ 0.21). The estimated ICC and CoR were
0.87 and 0.10 for CNFD, 0.93 and 0.23 for CNBD, and 0.94 and
0.04 for CNFL, respectively. Overall, CNFL and CNFD achieved
the highest values for repeatability and reproducibility,
whereas CNBD showed an acceptable consistency within
and between observers.
Statistical Analysis
Normality of the data was examined using the Kolmogorov-
Smirnov test and the appropriate test was applied for analysis.
Data are presented as mean 6 SD or median and interquartile
range. Four sets of analyses were conducted. First, the
demographic and clinical characteristic variables were com-
pared between control and diabetic groups as well as between
baseline and final visit. Second, using Toronto criteria,
participants with diabetes were stratified into those without
DPN (DPNve) and with DPN (DPNþve). Corneal nerve
parameters and established neuropathy measures were com-
pared among control, DPN–ve, and DPNþve. For the purpose
of the two aforementioned analyses, parametric data were
analyzed using the independent samples t-test, paired t-test,
one-way ANOVA, and Scheffe post hoc test (pairwise compar-
ison). Nonparametric data were analyzed using the v2 test,
Kruskal-Wallis test, and Mann-Whitney U test.
Third, a linear mixed model was used to examine changes
over time in the SNP parameters and whether the changes
were different in the DPN–ve and DPNþve groups compared
with controls. Because change in the SNP parameters (i.e.,
CNFD, CNBD, and CNFL) over time was one of the main
parameters of interest of the current study, they were
individually considered as response variables and time was
added to the model to test the linear effect of time on the
response variables. The first model contained CNFD as the
response variable, group (i.e., controls, DPN–ve, and DPNþve),
time, and time*group interaction as primary fixed effects of
interest and Type III sum of squares was selected. Group was
included as a time-invariant predictor variable to explore any
group differences over time.
The association between the initial CNFD parameter and
the change in this parameter was estimated by calculating the
covariance matrix. Here, the ‘‘variance components’’ option
was chosen and also the restricted maximum likelihood
estimates for parameters was used. The process of the
aforementioned model was repeated for CNBD and CNFL.
Depending on whether the time*group interaction was
statistically significant or not, a second set of fixed effects,
namely, sex, age at enrollment, duration of diabetes, HbA1c,
lipid profile, blood pressure, BMI, alcohol and tobacco
consumption, were included and their effects were examined.
A stepwise elimination of the variables with nonstatistically
significant P values also was applied.
The relation between risk factors and the changes of SNP
parameters in diabetic individuals, regardless of their neurop-
athy status, was analyzed with the latter model where all
relevant risk factors were included. Control participants were
excluded and group, as factor, was also removed from the
model.
Finally, to explore the relationship between changes in
corneal nerve parameters and functional measures of neurop-
athy, absolute change in all parameters was calculated
(Dparameter¼ parameter value at final visit – parameter value
at baseline). Bivariate correlations between absolute change of
corneal nerve parameters and neuropathy measures were
estimated using Pearson r and Spearman’s rho correlation
coefficients, where appropriate.
IBM SPSS 21 (IBM SPSS Statistics, IBM Corporation, Chicago,
IL, USA) was used for all statistical tests and a two-tailed a ¼
0.05 level of significance was considered for all analyses.
RESULTS
Table 1 shows the clinical characteristics and demographic
data of participants with diabetes and controls at baseline and
final visit. Approximately 95% of the entering participants were
Caucasians of European descent. There was no significant
difference between the mean age of participants with diabetes
and controls (P¼ 0.11). There were no statistically significant
TABLE 1. Demographic and Clinical Characteristics of the Participants at the Baseline and Final Visit
Parameter
Baseline Year 4 Follow-up P Value
Control, A Diabetes, B Control, C Diabetes, D A vs. B A vs. C B vs. D
n (male/female) 60 (26/34) 147 (71/76) 51 (22/29) 133 (67/66) 0.52* 0.98* 0.73*
Age, y 51.0 6 14.7 47.3 6 15.4 57.0 6 13.7 52.0 6 15.3 0.11† — —
Duration of diabetes, y 0 19.8 6 14.5 0 24.0 6 14.8 — — —
HbA1c, % 5.4 6 0.3 8.1 6 1.4 5.2 6 0.5 8.0 6 1.5 <0.001‡ <0.001§ 0.65#
Total cholesterol, mM 5.4 6 1.2 4.7 6 0.9 5.5 6 1.1 4.6 6 0.9 <0.001† 0.83§ 0.23§
HDL, mM 1.5 6 0.4 1.6 6 0.4 1.4 6 0.3 1.5 6 0.4 0.26‡ 0.06§ 0.78#
LDL, mM 3.5 6 1.1 2.7 6 0.8 3.5 6 1.1 2.5 6 0.7 <0.001† 0.96§ 0.07§
Triglycerides, mM 1.1 6 0.6 1.1 6 0.6 1.2 6 0.5 1.1 6 0.8 0.43‡ 0.27§ 0.40#
Systolic BP, mm Hg 116.1 6 13.6 121.0 6 16.5 117.1 6 13.7 118.8 6 12.1 0.03§ 0.88§ 0.12§
Diastolic BP, mm Hg 72.8 6 7.0 72.7 6 8.6 71.7 6 8.2 71.2 6 7.0 0.89† 0.27§ 0.13§
BMI, kg/m2 26.1 6 5.2 26.5 6 4.4 26.8 6 4.9 26.9 6 4.7 0.46† 0.42§ 0.02§
Alcohol consumption, units/wk 5.0 6 5.7 1.9 6 1.8 5.2 6 6.1 1.8 6 1.8 0.001‡ 0.78# 0.20#
Cigarettes smoked, no./d 6.7 6 11.5 5.1 6 8.0 1.3 6 5.2 1.3 6 5.6 0.74‡ <0.001# <0.001#
Results are expressed as mean 6 SD or counts for categorical variable.
* v2 test.
† Independent samples test.
‡ Mann-Whitney test.
§ Paired samples t-test.
# Wilcoxon test.
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differences between diabetes and control groups with respect
to high-density lipoprotein (HDL), triglycerides, diastolic blood
pressure (BP), BMI, and number of cigarettes smoked per day
(P > 0.25). Compared with controls, individuals with diabetes
had a higher HbA1c (% NGSP) (P < 0.001) and systolic BP (P¼
0.03) and lower total cholesterol (P < 0.001), low-density
lipoprotein (LDL) (P < 0.001), and alcohol consumption (P ¼
0.001).
The number of participants attending annual visits is
depicted graphically in Figure 1. Altogether, 184 participants
(89% of the baseline participants) completed the final visit.
Personal decision was the main reason for withdrawal (13
participants) followed by poor health (6 participants). Four
participants were lost to follow-up during the study period.
The median follow-up duration was 3.7 years (range, 3.4–4.3)
for the cohort.
As can be seen from Table 1, at final visit HbA1c showed a
clinically insignificant decrease in controls (mean difference
0.2%, P < 0.001), whereas it remained the same in participants
with diabetes (P ¼ 0.65). Lipid profile, BP, height, and alcohol
consumption did not differ at final visit compared with
baseline visit for both diabetes and control groups (P >
0.05). Although BMI showed a statistically significant increase
at the final visit in participants with diabetes (P¼ 0.02), there
was no change in controls (P¼0.42). Both control and diabetic
participants reported less smoking (number of cigarettes per
day) at the final visit compared with baseline (P ¼ 0.001).
Comparison of the mean or median change from baseline to
final visit in neuropathy measures of individuals with diabetes
showed that there were no significant changes in DNSS
(median 0 [0–0] vs. 0 [0–0], P¼0.56), cold sensation threshold
(median 28.5 [24.8–28.5] vs. 28.5 [26.0 vs. 28.5] 8C, P¼ 0.85),
vibration threshold (median 6.8 [2.5–6.8] vs. 6.6 [2.9–6.6] Hz,
P ¼ 0.42) and peroneal F-wave latency (mean 52.0 6 5.1 vs.
52.2 6 7.7 ms, P¼ 0.85). Neuropathy disability score (median
1.0 [0.0–1.0] vs. 0.0 [0.0–0.0], P < 0.01), warm sensation
threshold (median 37.6 [34.9–37.6] vs. 36.6 [34.8–36.6] 8C, P
< 0.01) and peroneal amplitude (mean 4.6 6 2.6 vs. 5.0 6 2.5
mV, P ¼ 0.03) showed slight but significant improvements,
whereas peroneal nerve conduction velocity (mean 45.3 6 6.0
vs. 44.4 6 5.8 m/s, P ¼ 0.03) was the only measure that
declined significantly from baseline to final visit.
Using Toronto criteria, in 147 individuals with type 1
diabetes, 39 (27%) were diagnosed with DPN at baseline. Table
2 delineates the outcomes of the SNP parameters and
neuropathy assessment by DPN status. Subbasal nerve plexus
parameters were significantly reduced in DPN–ve and DPNþve
groups compared with controls (P < 0.01). All established
neuropathy measures were significantly different between
groups. Quantitative sensory tests, peroneal F-wave latency,
and peroneal amplitude displayed greater deficits in the
DPNþve group compared with DPN–ve and control groups
(P < 0.05). Peroneal nerve conduction velocity was signifi-
cantly lower in both DPN–ve and DPNþve groups compared
with controls and there was also a significant difference
between DPN–ve and DPNþve groups (P < 0.05). Neuropathy
disability score and DNSS were significantly higher in DPNþve
group compared with control and DPN–ve groups (P < 0.001).
Figure 2 illustrates the 4-year time course for the SNP
parameters in the cohort by neuropathy status. The results of
the three created basic linear mixed model (LMM) analyses for
CNFD, CNBD, and CNFL can be found in Table 3. The Type III
tests of fixed effects shows overall test of significance for the
predictors included in the three basic models (LMM 1–3).
There was a significant effect of group for all three models;
however, the effect of time was not significant for any of them.
The Type III F-test for the interaction between group and time
was significant only in LMM1; therefore, no more models were
fitted for CNBD and CNFL as response variables.
A second subset of fixed effects was included in LMM1. On
sequential removal of nonstatistically significant fixed effects
and considering the lower resultant Akaike’s information
criteria for comparing alternative models,34 a final model
(LMM4) contained the fixed effects of group, time, age,
duration of diabetes, HbA1c, and the group*time interaction
was fitted. Parameter estimates and corresponding SEs, P
values and 95% confidence intervals are given in Table 4.
Group and time did not show a significant effect, whereas the
effects of age at enrollment (b¼0.06, P¼ 0.04) and duration
of diabetes (b ¼0.08, P ¼ 0.03) were significant. The LMM4
also showed a differential effect of time on the trajectory of
CNFD with the slope decreasing by 0.91 nerve/mm2 for
DPNþve individuals compared with controls (the reference
level of the group).
The examination of significant risk factors for corneal
neuropathy in diabetic individuals, irrespective of the baseline
neuropathy status, showed that CNFD was associated with
HbA1c (b ¼ 0.58, P ¼ 0.03) and duration of diabetes (b ¼
0.08, P¼0.03). Corneal nerve branch density was found to be
affected by the duration of diabetes (b¼0.21, P¼ 0.01) and
smoking (b ¼ 0.25, P ¼ 0.04). No statistically significant
FIGURE 1. Distribution and number of participants examined at various time points.
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association was found between CNFL and the included risk
factors.
Because peroneal nerve conduction velocity was the only
measure that showed a significant worsening in the diabetes
group, we sought to compare the trajectories of this parameter
between groups using an additional mixed model (LMM5). The
above-mentioned basic model was repeated with peroneal
nerve conduction velocity as the response variable. There was
a significant effect of time (P < 0.01) and group (P < 0.01), but
the group*time interaction was not significant (P ¼ 0.92),
indicating that the observed time effect is not different
between groups.
In the diabetic group, bivariate correlation revealed a
modest association between absolute changes of CNBD and
peroneal nerve conduction velocity (Pearson r ¼ 0.23, P ¼
0.02). In the DPNþve group, there was a significant correlation
between CNBD and peroneal nerve conduction velocity
(Pearson r ¼ 0.38, P ¼ 0.05). The absolute change in CNFL
was also positively correlated with the cold sensation threshold
(Pearson r ¼ 0.40, P ¼ 0.03).
DISCUSSION
In vivo assessment of the SNP morphology using CCM has
emerged as a valuable clinical modality to improve our
understanding of the relationship between this rich nerve
plexus and various ocular and systemic conditions and
diseases. As reviewed in more detail elsewhere,35,36 morpho-
metric evaluation of the SNP has been used to diagnose, assess,
and follow-up ocular surface conditions, including ocular
allergy, dry eye, infectious keratitis, and glaucoma and after
keratorefractive surgery and contact lens wear. Currently,
considerable evidence exists that advocates the utility of CCM
for assessment of small nerve fiber pathology induced by
systemic and neurological conditions, in particular DPN. This
study examined the longitudinal aspect of the utility of CCM to
serve as an acceptable measure of DPN in clinical research and
practice.
We report data from a cohort of individuals with type 1
diabetes (n¼147) and healthy controls (n¼60) collected from
baseline to a median duration of 3.7 years. Although the
TABLE 2. Baseline Comparison of Corneal Nerve Parameters and Neuropathy Measures in the Study Participants According to Presence and
Absence of Neuropathy Defined by Toronto Criteria
Characteristics
DPN Status at Baseline
P Group DifferenceControls, n ¼ 60 DPNve, n ¼ 108 DPNþve, n ¼ 39
Corneal nerve parameters
CNFD, no./mm2 22.3 6 8.0 18.3 6 7.1 16.3 6 8.3 <0.001*
Controls vs. DPNve, DPNþve†
CNBD, no./mm2 35.1 6 23.8 24.2 6 17.4 23.7 6 20.9 0.003‡
Controls vs. DPNve, DPNþve§
CNFL, no./mm2 18.1 6 3.7 16.0 6 3.8 15.0 6 4.3 <0.001*
Controls vs. DPNve, DPNþve†
Quantitative sensory tests
Cold sensation threshold, 8C 28.4 6 2.8 27.4 6 5.1 23.4 6 7.2 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Warm sensation threshold, 8C 38.0 6 4.1 37.4 6 3.8 41.6 6 3.7 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Vibration threshold, Hz 7.0 6 8.1 8.7 6 10.3 25.7 6 22.2 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Nerve conduction studies
Peroneal F latency, ms 49.6 6 5.2 51.5 6 4.9 55.7 6 5.0 <0.001*
Controls vs. DPNþve†
DPNve. vs DPNþve†
Peroneal nerve amplitude, mV 4.7 6 2.3 5.2 6 2.7 2.7 6 1.8 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Peroneal nerve conduction velocity, m/s 49.0 6 5.5 46.7 6 5.0 39.6 6 5.9 <0.001*
Controls vs. DPNve, DPNþve†
DPNve vs. DPNþve†
Neuropathy disability score (0–10) 0.4 6 0.9 0.6 6 0.9 2.2 6 1.5 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Diabetic neuropathy symptom score (0–4) 0.1 6 0.3 0.2 6 0.5 1.1 6 1.0 <0.001‡
Controls vs. DPNþve§
DPNve vs. DPNþve§
Outcomes are presented as mean 6 SD.
* One-way ANOVA test.
† Scheffe post hoc test.
‡ Kruskal-Wallis test.
§ Mann-Whitney U test.
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stability of corneal nerve morphology has been previously
demonstrated in a 3-year longitudinal study in healthy
individuals,37 to our knowledge no previous study has
examined the dynamic natural course of SNP microstructures
in relation to DPN. With reference to the lack of previous
investigation concerning the natural history of corneal nerves
in diabetes, the present study is a positive response and
attempts to fill this research gap.
At the baseline visit, age was matched between participants
with diabetes and controls. Diabetic participants showed
moderate glycemic control and excellent control of cardiovas-
cular risk factors, including the BP and lipid profile in
accordance with the current treatment guidelines.38 The lower
level of total cholesterol and LDL cholesterol in our diabetic
patients as compared with controls is attributed to the fact that
35% were receiving lipid-lowering medications.
Comparison of the clinical parameters at baseline and final
visit showed that there were no clinically significant changes to
health or metabolic and anthropometric measurements,
indicating stable glucose control and desirable maintenance
of cardiovascular risk factors. Although the Hawthorne effect39
may have been involved, the finding of lower alcohol
consumption in the diabetic patients at baseline, which is
maintained at follow-up, reflects good diabetes education. And
the significant reduction in tobacco consumption over time in
both diabetic patients and control subjects presumably reflects
overall population level of education to stop smoking.
Except for peroneal nerve conduction velocity, with a
statistically significant but clinically trivial decline (0.9 m/s),
the remaining established measures of neuropathy remained
unchanged or improved slightly from baseline to the final visit.
However, LMM5 showed that changes in peroneal nerve
conduction velocity in DPNþve and DPN–ve patients did not
differ significantly from controls, indicating a similar effect of
time for groups. The low rate of change over time in these
measures may be attributed to the following: the maintenance
of a healthy lifestyle and compliance with medical advice
among our diabetic cohort, the inclusion of participants with
only mild neuropathy, and the relatively short duration of
study. Negligible worsening or no progression of the traditional
measures of DPN also has been observed in the placebo arm of
a recent interventional study40 of 227 patients with predom-
inantly type 2 diabetes, but with substantially worse glycemic
control at baseline (8.8% 6 1.9%) and a reduction of 0.67% 6
1.41% over 4 years. Our findings are further supported by a 3-
FIGURE 2. Longitudinal course of CNFD (A), CNBD (B), and CNFL (C)
over time. On each graph, the solid line represents control
participants, the dashed line represents diabetic participants without
neuropathy, and the dotted line represents diabetic participants with
neuropathy. Error bars indicate mean 6 SEM.
TABLE 3. Results of Type III Tests of Fixed Effects From the Three
Initial LMM Analysis
LMM1 LMM2 LMM3
F P F P F P
Intercept 1420.0 <0.001 423.2 <0.001 4254.4 <0.001
Group 8.2 <0.001 7.4 0.001 10.9 <0.001
Time, y 0.03 0.87 1.8 0.18 0.5 0.49
Group*Time 4.0 0.02 1.4 0.24 1.6 0.20
Dependent variables were CNFD in LMM1, CNBD in LMM2, and
CNFL in LMM3.
TABLE 4. Maximum Likelihood of the Fixed Effect Parameters for
LMM4, With CNFD as the Continuous Response Variable
Parameter Estimate (95% CI) SE P Value
Intercept 27.57 (23.01 to 32.12) 2.32 <0.001
Time, y 0.35 (0.10 to 0.80) 0.23 0.13
Group
DPNþve 1.36 (5.17 to 2.45) 1.94 0.48
DPNve 1.33 (4.18 to 1.52) 1.45 0.36
Controls 0* 0
Age at enrolment, y 0.06 (0.12 to 0.00) 0.03 0.04
Duration of diabetes, y 0.08 (0.16 to 0.01) 0.04 0.03
HbA1C, % 0.41 (0.89 to 0.08) 0.25 0.10
Group*Time
DPNþve * Time 0.91 (1.63 to 0.20) 0.37 0.01
DPNve * Time 0.26 (0.82 to 0.31) 0.30 0.37
Controls * Time 0* 0
CI, confidence interval.
* This parameter is set to zero because it is the reference level of the
group.
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year longitudinal study of 62 subjects with predominantly type
2 diabetes and good glycemic control (HbA1c 7.23% 6 1.03%),
which interestingly demonstrated stability in a range of
neurological examinations, symptom scores, autonomic test-
ing, QST, and NCS with worsening only in the sural nerve
amplitude and the axon-reflex vasodilation test, a measure of
small fiber neuropathy.41
All three SNP parameters were significantly reduced in
diabetic participants without and with neuropathy at the
baseline visit. This finding is consistent with other studies,
which also show a depletion of SNP tissue in diabetic patients
without and with DPN, reflecting early subclinical small fiber
damage.22–24,42 Based on the reported association of SNP
parameters and DPN severity,23,24 we hypothesized that
participants with diabetes and DPN would demonstrate
quicker deterioration of SNP tissue than those without DPN.
To examine this hypothesis, we built several LMMs. Such
models afford robust methods of analyzing longitudinal data
with repeated measurements, in particular when the data are
incomplete or unbalanced due to missing data, dropouts, or
differences in observation time points.34
According to the three basic mixed models developed here
and regardless of group, there was no significant effect of time
for any of the three SNP parameters. A group*time interaction
term was not significant for CNBD or CNFL (P¼ 0.24 and P¼
0.20), indicating that the presence or absence of DPN at
baseline did not appear to impact CNBD and CNFL changes
over time. Mean CNBD (23.7 6 20.9 vs. 22.7 6 16.9, no./
mm2) and CNFL (15.0 6 4.3 vs. 14.4 6 4.1 mm/mm2) declined
slightly over 4 years in the neuropathy group, but to an extent
that is neither clinically nor statistically significant.
However, the Type III F-test for the interaction between
time and group was statistically significant for CNFD (P¼0.02),
suggesting that the relationship of time with CNFD change
varies depending on the group. The LMM4 (Table 4)
demonstrated that whereas CNFD trajectories were not
statistically different between DPN–ve and controls, the mean
CNFD decreased significantly in the DPNþve group during
follow-up, with a loss of approximately 1 nerve/mm2 per year.
This observed CNFD change was best predicted by participant
age and duration of diabetes (both P < 0.05). One may
anticipate that such a change would be influenced by glycemic
control; however, HbA1c did not reach statistical significance
(P ¼ 0.10) in LMM4, where CNFD was considered as a
dependent variable, possibly because of the relative stability of
this factor during the study period. Although the outcome of
CNFD decline indicates dynamic structural small nerve fiber
damage at the SNP, the relevance of CNFD change in the
neuropathy group and the relative stability of CNBD and CNFL
are not clear. Disparate changes to these three corneal nerve
parameters also have been reported in diabetic individuals after
improvement in risk factors for DPN27 and after simultaneous
pancreas and kidney transplantation,43 suggesting a complex,
dynamic, and perhaps nonlinear relationship between these
parameters.
The baseline cross-sectional findings in the present study
confirmed that all three SNP parameters were reduced in the
neuropathy group compared with controls. The parameter that
underwent the most marked reduction over time was CNFD.
This suggests that branch damage (thinner branches emanating
from major nerves) might represent the primary pathological
change in DPN, whereas CNFD (a parameter related to the
major nerve trunks) deterioration occurs later. The reduction
in CNFD along with a nonsignificant decline of the other two
parameters also may suggest degeneration of major nerve
trunks with concomitant regeneration reflected by an increase
in the CNBD and CNFL. Therefore, it is conceivable that loss
and indeed repair of different SNP parameters may occur at
different stages of the disease.
Limited studies are available documenting the link between
corneal small nerve fiber change and risk factors of DPN.21,27,44
In the present study, when the data were restricted to include
only diabetic individuals and on removal of the effect of group
in the LMMs, we found that every 1-unit increase of HbA1c was
associated with a decrease of approximately 0.6 nerve/mm2 in
CNFD. There also was a negative effect of diabetes duration on
CNFD and CNBD. Each 10-year increase of diabetes duration at
baseline resulted in 0.8 and 2.0 nerve/mm2 decline of central
corneal CNFD and CNBD, respectively. Corneal nerve branch
density was also significantly affected by smoking. Increasing
one cigarette per day had a negative effect of 0.25 nerve/mm2.
These results demonstrate the link between risk factors of
DPN and morphologic parameters of corneal nerves. We have
no clear explanation why HbA1c has an effect on CNFD, but
not CNBD and CNFL. Nevertheless, this finding is consistent
with the study of Tavakoli et al.27 who reported a significant
correlation between changes in HbA1c and CNFD (r¼0.52, P
< 0.01) but not for CNBD and CNFL. In a study of 38 type 1
diabetic patients with and without neuropathy, Ishibashi et
al.44 reported time-dependent effects of HbA1c on SNP
parameters. Although nerve beading frequency was positively
correlated with the mean HbA1c levels at time of, or up to 3
months before CCM examination, no significant association
was found between CNFD and CNFL with HbA1c up to 6 years
before CCM examination.
These findings emphasize the importance of including
different SNP parameters in future studies, where these
parameters are to be used as measures of small nerve fiber
damage and in particular repair. Additionally, in this study, only
the central cornea has been investigated. Recent studies have
revealed that loss of corneal nerve structure in the SNP mainly
occurred at the inferior whorl, which is slightly more distal
than the central cornea and may therefore be expected to
show more marked pathology.45,46 Further longitudinal work
assessing the inferior whorl as opposed to the central cornea
may provide additional insights and ability to discriminate
change in relation to DPN.
In previous cross-sectional studies, SNP parameters have
been shown to correlate with functional and structural
measures of neuropathy.19,23,25 Quattrini et al.19 reported a
significant correlation between CNFD versus NDS (r¼0.30, P
¼ 0.03) and cold sensation threshold (r¼0.40, P < 0.01). In a
subsequent study, moderate correlations were found between
NDS and corneal nerve parameters (r, 0.48 to 0.58; P <
0.001).23 In a recent study by Sivaskandarajah et al.,25 CNFD,
CNBD, and CNFL were related to cold sensation threshold (r,
0.32 to 0.37; P  0.01). In this longitudinal study, we examined
the relationship of change in corneal nerve parameter with
conventional measures of neuropathy by calculating the
absolute change from baseline to final visit for participants
with diabetes. We found a modest correlation between CNBD
and peroneal conduction velocity (Pearson r¼ 0.23, P¼ 0.02).
When the data were restricted to the DPNþve group, this
correlation increased to 0.38. Furthermore, CNFL also corre-
lated to cold sensation threshold (r ¼ 0.40, P ¼ 0.03), which
indicates that SNP parameters do change in a fashion
comparable with some traditional measures of neuropathy.
The key strengths of this study are its longitudinal nature,
inclusion of a range of traditional neuropathy measures (small
and large nerve fiber dysfunction) in a relatively large number
of type 1 diabetic participants, the consistency and strict
adherence to technical and methodological procedures, such
as capturing and selection criteria of the SNP images, and using
a fully automated image analysis algorithm, which is essential
to eliminate the variability associated with manual and semi-
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automated analysis. Thus, we used a fully automated image
analysis algorithm that has been validated and compared
against the manual and semiautomated analysis33,42,47 in
individuals with diabetes.
A limitation of this study is that most type 1 participants
were enrolled from specialized clinics, where the glycemic and
cardiovascular factors were optimally controlled, which may
not represent the typical population with type 1 diabetes.
Additionally, 4 years of study might be insufficient to discern
changes over time, particularly in the case of patients with mild
neuropathy or the limited number of apparently motivated
participants with well-controlled diabetes available in the
neuropathy group.
In conclusion, the findings presented herein provide
evidence that CCM has the potential to track the structural
alterations of the small nerve fibers in DPN. Furthermore, these
findings support the notion that quantification of the SNP
morphology has a substantial potential to be used as an
appropriate adjunct measure to conventional measures of
DPN.
Acknowledgments
Supported by grants from the National Health and Medical
Research Council of Australia (497230) and the JDRFI (8-2008-
362). The authors alone are responsible for the content and
writing of the paper.
Disclosure: C. Dehghani, None; N. Pritchard, None; K.
Edwards, None; D. Vagenas, None; A.W. Russell, None; R.A.
Malik, None; N. Efron, None
References
1. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged
severity of various types of diabetic neuropathy, retinopathy
and nephropathy in a population-based cohort: the Rochester
Diabetic Neuropathy Study. Neurology. 1993;43:817–824.
2. Chin RL, Rubin M. Diabetic neuropathy. In: Poretsky L, ed.
Principles of Diabetes Mellitus. New York, NY: Springer;
2010:357–370.
3. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot
disorders: a clinical practice guideline (2006 revision). J Foot
Ankle Surg. 2006;45:S1–S66.
4. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The
quality of life and economic burden of neuropathy in diabetic
patients in Germany in 2002: results from the diabetic
microvascular complications (DIMICO) study. Diabetes Res
Clin Pract. 2008;81:223–230.
5. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence
and impact on quality of life of peripheral neuropathy with or
without neuropathic pain in type 1 and type 2 diabetic
patients attending hospital outpatient clinics. Diabetes Metab.
2009;35:206–213.
6. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms vs
nerve conduction studies to diagnose diabetic sensorimotor
polyneuropathy. Muscle Nerve. 2010;42:157.
7. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic
somatic neuropathies. Diabetes Care. 2004;27:1458–1486.
8. Dyck PJ, Argyros B, Russell JW, et al. Multicenter trial of the
proficiency of smart quantitative sensation tests. Muscle
Nerve. 2014;49:645–653.
9. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms
versus nerve conduction studies to diagnose diabetic senso-
rimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve.
2010;42:157–164.
10. Litchy WJ, Albers JW, Wolfe J, et al. Proficiency of nerve
conduction using standard methods and reference values (The
Cl. NPhys Trial 4 Investigators). Muscle Nerve. 2014;doi:10.
1002/mus.24243.
11. Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal
microscopy detects neuropathy in subjects with impaired
glucose tolerance. Diabetes Care. 2014;37:2643–2646.
12. Ziegler D, Papanas N, Zhivov A, et al. Early detection of nerve
fiber loss by corneal confocal microscopy and skin biopsy in
recently diagnosed type 2 diabetes. Diabetes. 2014;63:2454–
2463.
13. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology
in diabetic patients with minimal but progressive neuropathy.
Diabetologia. 2005;48:578–585.
14. Lauria G, Lombardi R, Camozzi F, Devigili G. Skin biopsy for
the diagnosis of peripheral neuropathy. Histopathology. 2009;
54:273–285.
15. Li C, Bunner AE, Pippin JJ. From animal models to clinical
practicality: lessons learned from current translational pro-
gress of diabetic peripheral neuropathy. In: Souayah N, ed.
Peripheral Neuropathy—A New Insight into the Mechanism,
Evaluation and Management of a Complex Disorder. Rijeka,
Hungary: InTech; 2013:29–76.
16. Varkonyi T, Putz Z, Keresztes K, et al. Current options and
perspectives in the treatment of diabetic neuropathy. Curr
Pharm Des. 2013;19:4981–5007.
17. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL.
Diabetic neuropathy: clinical manifestations and current
treatments. Lancet Neurol. 2012;11:521–534.
18. Malik RA. From the bedside to the bench and back again, with
corneal confocal microscopy. Invest Ophthalmol Vis Sci.
2014;55:1231.
19. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers
of small fiber damage in human diabetic neuropathy. Diabetes.
2007;56:2148–2154.
20. Malik RA, Kallinikos P, Abbott CA, et al. Corneal confocal
microscopy: a non-invasive surrogate of nerve fibre damage
and repair in diabetic patients. Diabetologia. 2003;46:683–
688.
21. Edwards K, Pritchard N, Vagenas D, Russell A, Malik RA, Efron
N. Utility of corneal confocal microscopy for assessing mild
diabetic neuropathy: baseline findings of the LANDMark study.
Clin Exp Optom. 2012;95:348–354.
22. Ahmed A, Bril V, Orszag A, et al. Detection of diabetic
sensorimotor polyneuropathy by corneal confocal microscopy
in Type 1 diabetes: a concurrent validity study. Diabetes Care.
2012;35:821–828.
23. Tavakoli M, Quattrini C, Abbott C, et al. Corneal confocal
microscopy: a novel noninvasive test to diagnose and stratify
the severity of human diabetic neuropathy. Diabetes Care.
2010;33:1792–1797.
24. Petropoulos IN, Alam U, Fadavi H, et al. Corneal nerve loss
detected with corneal confocal microscopy is symmetrical and
related to the severity of diabetic polyneuropathy. Diabetes
Care. 2013;36:3646–3651.
25. Sivaskandarajah GA, Halpern EM, Lovblom LE, et al. Structure-
function relationship between corneal nerves and conven-
tional small-fiber tests in type 1 diabetes. Diabetes Care. 2013;
36:2748–2755.
26. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, et al. Corneal
confocal microscopy detects early nerve regeneration in
diabetic neuropathy after simultaneous pancreas and kidney
transplantation. Diabetes. 2013;62:254–260.
27. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal
microscopy detects improvement in corneal nerve morphol-
ogy with an improvement in risk factors for diabetic
neuropathy. Diabet Med. 2011;28:1261–1267.
Corneal Nerve Changes in Diabetic Neuropathy IOVS j December 2014 j Vol. 55 j No. 12 j 7989
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933678/ on 02/07/2017
28. Pritchard N, Edwards K, Dehghani C, et al. Longitudinal
assessment of neuropathy in type 1 diabetes using novel
ophthalmic markers (LANDMark): study design and baseline
characteristics. Diabetes Res Clin Pract. 2014;104:248–256.
29. Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies:
update on definitions, diagnostic criteria, estimation of
severity, and treatments. Diabetes Care. 2010;33:2285–2293.
30. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen
PH. A multicenter study of the prevalence of diabetic
peripheral neuropathy in the United Kingdom hospital clinic
population. Diabetologia. 1993;36:150–154.
31. Meijer J, Smit A, Sonderen E, Groothoff J, Eisma W, Links T.
Symptom scoring systems to diagnose distal polyneuropathy
in diabetes: the Diabetic Neuropathy Symptom score. Diabet
Med. 2002;19:962–965.
32. Vagenas D, Pritchard N, Edwards K, et al. Optimal image
sample size for corneal nerve morphometry. Optom Vis Sci.
2012;89:812–817.
33. Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA.
Automatic analysis of diabetic peripheral neuropathy using
multi-scale quantitative morphology of nerve fibres in corneal
confocal microscopy imaging. Med Image Anal. 2011;15:738–
747.
34. Shek DT, Ma C. Longitudinal data analyses using linear mixed
models in SPSS: concepts, procedures and illustrations.
ScientificWorldJournal. 2011;11:42–76.
35. Villani E, Mantelli F, Nucci P. In-vivo confocal microscopy of
the ocular surface: ocular allergy and dry eye. Curr Opin
Allergy Clin Immunol. 2013;13:569–576.
36. Villani E, Baudouin C, Efron N, et al. In vivo confocal
microscopy of the ocular surface: from bench to bedside.
Curr Eye Res. 2014;39:213–231.
37. Dehghani C, Pritchard N, Edwards K, et al. Morphometric
stability of the corneal subbasal nerve plexus in healthy
individuals: a 3-year longitudinal study using corneal confocal
microscopy. Invest Ophthalmol Vis Sci. 2014;55:3195–3199.
38. American Diabetes Association. Standards of medical care in
diabetes—2014. Diabetes Care. 2014;37:S14–S80.
39. McCambridge J, Witton J, Elbourne DR. Systematic review of
the Hawthorne effect: new concepts are needed to study
research participation effects. J Clin Epidemiol. 2014;67:267–
277.
40. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of
antioxidant treatment with a-lipoic acid over 4 years in
diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care.
2011;34:2054–2060.
41. Gibbons CH, Freeman R, Tecilazich F, et al. The evolving
natural history of neurophysiologic function in patients with
well-controlled diabetes. J Peripher Nerv Syst. 2013;18:153–
161.
42. Petropoulos IN, Alam U, Fadavi H, et al. Rapid automated
diagnosis of diabetic peripheral neuropathy with in vivo
corneal confocal microscopy. Invest Ophthalmol Vis Sci.
2014;55:2071–2078.
43. Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal
microscopy detects early nerve regeneration after pancreas
transplantation in patients with type 1 diabetes. Diabetes
Care. 2007;30:2608–2612.
44. Ishibashi F, Okino M, Ishibashi M, et al. Corneal nerve fiber
pathology in Japanese type 1 diabetic patients and its
correlation with antecedent glycemic control and blood
pressure. J Diabetes Investig. 2012;3:191–198.
45. Davidson EP, Coppey LJ, Kardon RH, Yorek MA. Differences
and similarities in development of corneal nerve damage and
peripheral neuropathy and in diet-induced obesity and type
2 diabetic rats. Invest Ophthalmol Vis Sci. 2014;55:1222–
1230.
46. Edwards K, Pritchard N, Gosschalk K, et al. Wide-field
assessment of the human corneal subbasal nerve plexus in
diabetic neuropathy using a novel mapping technique.
Cornea. 2012;31:1078–1082.
47. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA,
Efron N. Fully automated, semiautomated, and manual
morphometric analysis of corneal subbasal nerve plexus in
individuals with and without diabetes. Cornea. 2014;33:696–
702.
Corneal Nerve Changes in Diabetic Neuropathy IOVS j December 2014 j Vol. 55 j No. 12 j 7990
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933678/ on 02/07/2017
